Fool.com Headlines http://ift.tt/1x3bm9n Generic and specialty drugmakers have seen profits soar on the heels of the so-called patent cliff. Teva Pharmaceutical Industries, however, hasn't followed in their footsteps for the most part. Even so, the company's shares look like a compelling buy for three reasons.
No comments:
Post a Comment